This clinical trial is focused on studying a condition known as primary immune thrombocytopenia (ITP). ITP is an autoimmune disorder where the body’s immune system mistakenly attacks and destroys its own platelets, which are blood cells that help with clotting. This can lead to easy or excessive bruising and bleeding. The treatment being tested in this study is called efgartigimod, also known by its code name ARGX-113. Efgartigimod is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the long-term safety of efgartigimod in adult patients with primary immune thrombocytopenia. Participants in the study will receive efgartigimod infusions and will be monitored over a period of time to assess how safe the treatment is and how well it works in managing the condition. The study will involve regular visits to the clinic for infusions and check-ups, where doctors will keep track of the participants’ health and any changes in their platelet counts.

Throughout the study, researchers will collect information on the frequency and severity of any side effects, as well as changes in vital signs and laboratory test results. The study aims to provide valuable insights into the long-term use of efgartigimod for treating primary immune thrombocytopenia, helping to determine if it is a safe and effective option for patients with this condition.